ERAL1 and breast carcinoma: The occupation of the binding pocket of hERα by ER targeting small molecules can prevent estrogen from binding to such active site and thus abrogates estrogenic downstream signaling which precedes undue proliferation, as implicated in estrogen receptor positive breast cancer.